|
|
One-to-One We
listen, understand, educate and support. | ||
|
December 2006 | |||
|
In
This Issue ·
Getting The Word Out! ·
Virginia G. Piper Cancer Center Events ·
Support
Group Information ·
Please
Help Us Help
Others ·
Predictive Genomics Testing Breast
Buds, Inc. A
501c3 Corporation Tax
ID# 84-1666215
Helpline 480.657.0500 Nancy
Phleger 623.486.0375 If
You Need Help Give
Us A Call!!! Our
Breast
Buds, Inc. A
501(c)(3) non-profit organization extends a supportive hand and heart to
those diagnosed with breast cancer, by offering one-to-one emotional
support, education and wellness guidance, from diagnosis through treatment
into recovery. Disclaimer The
information provided herein is supplemental
only and
NOT meant to replace the advice from your doctor, trained
medical staff, or
any medical provider. |
Predictive Genomics Testing
The
days of “one-size-fits-all” medicine are fast coming to an end.
An advanced, individualized approach to health care based on
breakthrough predictive genomic testing is now available.
They
are predictive genomic tests that measure individual genetic
variations called single nucleotide polymorphisms (SNPs). Under
the influence of environmental triggers, these variations can
make a person more or less prone to develop to certain diseases
or physiological imbalances.
The
tests provide a previously unseen glimpse into each person’s
potential health future, assessing their genetic susceptibility
to conditions such as heart disease, osteoporosis, chemical
sensitivity, adverse drug reactions, allergies, and immune
disorders.
After
careful evaluation of selected sections of each patient’s
genetic “blueprint,” a carefully targeted, customized health
care plan to help reduce disease risk even before pre-disease
imbalances become apparent.
An example is the OsteoGenomic™ Profile, used to identify
patients who may be more genetically susceptible to developing
osteoporosis.
Using a single blood or mouth rinse sample, this advanced test
evaluates genetic variations, called single nucleotide
polymorphisms (SNPs), that influence how bone tissue is formed
and broken down in the body. These genetic variations influence
how an individual utilizes key nutrients such as calcium or
vitamin D in the bone-building process. The SNPs do not cause
the disease, but their presence may indicate the potential for
increased risk as environmental, dietary, and lifestyle factors
interact with them. For
example the results of this test may indicate if an individual
will respond better to Vitamin D or calcitonin or Fosomax to
improve bone mass.
The estrogenomic test is more complete.
It tests several areas of concern to women who have had
or are at increased risk of breast cancer.
Since estrogen becomes an issue in these individuals this
panel includes testing for disease markers associated with
several diseases associated with estrogen or lack of estrogen.
This panel includes the osteoporosis panel as well as
markers for heart disease, joint inflammation,
how an individual metabolizes estrogen to safer forms and
ability to remove toxins from the system.
The
genetic markers on each test are carefully selected. They do not
indicate certainty of developing disease, but only the potential
for increased risk as the genetic variation is exposed to
certain lifestyle and environmental triggers. By modifying the
factors that influence the expression of these genetic
variations, patients may gain the chance to exert a greater
degree of control over their future health.
This
genomics-based approach is built on a newly emerging integrative
and individualized health care model. As recently stated by the
Centers for Disease Control and Prevention, “virtually all human
diseases result from the interaction of genetic susceptibility
factors and modifiable environmental factors, broadly defined to
include infections, chemical, physical, nutritional, and
behavioral factors” (CDC, August, 2000).
Dr. Dana Keaton Center For Natural Medicine Phoenix, AZ 85007 (602) 266-4670 www.centerfornaturalmedicine.com/ | ||
